Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.
A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine-5'-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
49
Study drug
GSK Investigational Site
Christchurch, New Zealand
GSK Investigational Site
Wellington, New Zealand
To characterise the dose response curve following repeat inhaled doses of FP for 5 days in the AMP challenge model.
Time frame: 5 days
Safety following multiple AMP challenges: Adverse events
Time frame: 5 days
Plasma concentrations of FP and derived pharmacokinetic parameters
Time frame: 5 days
Exhaled nitric oxide concentrations
Time frame: 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.